The Association of Urinary Sclerostin and Renal Magnesium Handling in Type 2 Diabetic Patients with Chronic Kidney Disease

被引:3
|
作者
Wu, Ching-Fang [1 ,2 ]
Liou, Hung-Hsiang [3 ,4 ]
Kuo, Chin-Chi [5 ,6 ]
Tsai, Ming-Hsien [7 ]
Chang, Min-Yu [1 ,4 ]
Lee, Yi-Che [1 ,8 ]
Lin, Tsun-Mei [9 ,10 ]
Hung, Shih-Yuan [1 ,4 ]
机构
[1] I Shou Univ, Coll Med, Sch Med, Kaohsiung, Taiwan
[2] E Da Canc Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[3] Hsin Jen Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan
[4] E Da Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[5] China Med Univ, China Med Univ Hosp, Big Data Ctr, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan
[7] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan
[8] E Da Dachang Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan
[9] I Shou Univ, Dept Med Lab Sci, Kaohsiung, Taiwan
[10] E Da Hosp, Dept Med Res, Kaohsiung, Taiwan
关键词
Chronic kidney disease; Sclerostin; Fractional excretion of calcium; Fractional excretion of magnesium; Type 2 diabetes mellitus; METABOLISM; CALCIUM;
D O I
10.1159/000516844
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: Sclerostin could enhance renal excretion of calcium (Ca) and phosphate (P). The association between sclerostin and magnesium (Mg) has not yet discovered. In patients with type 2 diabetes mellitus (T2DM) or chronic kidney disease (CKD), higher serum sclerostin and altered renal excretion of Ca, P, and Mg were detected. Therefore, we tried to evaluate if there was any association between sclerostin and fractional excretion of Ca, P, and Mg (FeCa, FeP, and FeMg) in T2DM with CKD. Methods: In this prospective cohort study, 43 T2DM patients without CKD or with CKD stage 1-5 were enrolled. Values of parameters, including serum and urine sclerostin, were collected at baseline and 6 months later. For baseline data, the Mann-Whitney U test, chi(2) test, or Spearman's correlation were used. For multivariate repeated measurement analysis, generalized estimating equation (GEE) model was utilized. Results: Patients with lower estimated glomerular filtration rate had higher serum sclerostin, FeP, FeMg, and lower FeCa. By correlation analysis, serum sclerostin was negatively associated with FeCa (p = 0.02) and positively associated with FeP (p = 0.002). The urine sclerostin to creatinine ratio (Uscl/Ucre) was positively correlated with FeP (p = 0.007) and FeMg (p = 0.005). After multivariate analyses by GEE model, serum sclerostin was still inversely associated with FeCa, while Uscl/Ucre was significantly associated with FeMg. On the other hand, FeP lost its associations with serum sclerostin or Uscl/Ucre. Conclusion: In our study population of T2DM patients with or without CKD, the inverse correlation between serum sclerostin and FeCa could not be explained by the calciuric effect of sclerostin. In addition, a newly discovered positive association between urinary sclerostin and FeMg indicated a possible role of urinary sclerostin in regulating renal Mg handling especially over distal convoluted tubules.
引用
收藏
页码:514 / 522
页数:9
相关论文
共 50 条
  • [1] Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients
    Boltenstal, Henrik
    Qureshi, Abdul Rashid
    Behets, Geert J.
    Lindholm, Bengt
    Stenvinkel, Peter
    D'Haese, Patrick C.
    Haarhaus, Mathias
    CALCIFIED TISSUE INTERNATIONAL, 2019, 104 (02) : 214 - 223
  • [2] Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients
    Henrik Boltenstål
    Abdul Rashid Qureshi
    Geert J. Behets
    Bengt Lindholm
    Peter Stenvinkel
    Patrick C. D’Haese
    Mathias Haarhaus
    Calcified Tissue International, 2019, 104 : 214 - 223
  • [3] Association of urinary calcium excretion with chronic kidney disease in patients with type 2 diabetes
    Wang, Yanru
    Chen, Yuxing
    Yu, Yanping
    Pan, Xin
    Fu, Guoxiang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (08) : 2715 - 2723
  • [4] Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes
    Zhu, Huanhuan
    Liu, Xi
    Zhang, Chengning
    Li, Qing
    An, Xiaofei
    Liu, Simeng
    Wu, Lin
    Zhang, Bo
    Yuan, Yanggang
    Xing, Changying
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (11)
  • [5] Uremic toxicity and sclerostin in chronic kidney disease patients
    Desjardins, Lucie
    Liabeuf, Sophie
    Oliveira, Rodriguo B.
    Louvet, Loic
    Kamel, Said
    Lemke, Horst-Dieter
    Vanholder, Raymond
    Choukroun, Gabriel
    Massy, Ziad A.
    NEPHROLOGIE & THERAPEUTIQUE, 2014, 10 (06): : 463 - 470
  • [6] GLYCEMIC VARIABILITY IN TYPE 2 DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE
    Steriade, Oana
    Pantea-Stoian, Anca
    Savu, Octavian
    Florentiu, Ariel
    Cioca, Gabriela
    Purcarea, Victor Lorin
    Elian, Viviana
    INTERDIAB 2016: DIABETES MELLITUS AS CARDIOVASCULAR DISEASE, 2016, : 453 - 457
  • [7] Association of urinary angiotensinogen with renal arteriolar remodeling in chronic kidney disease
    Kanamitsu, Takafumi
    Kohagura, Kentaro
    Zamami, Ryo
    Nakamura, Takuto
    Oshiro, Nanako
    Miyagi, Tsuyoshi
    Nakamura, Koshi
    Ohya, Yusuke
    JOURNAL OF HYPERTENSION, 2022, 40 (04) : 650 - 657
  • [8] The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease
    Feng, Xinhui
    Zheng, Yuqi
    Guan, Haochen
    Zhou, Xun
    Xu, Ying
    Zhang, Xiaoli
    Fu, Chensheng
    Xiao, Jing
    Ye, Zhibin
    ENDOCRINE RESEARCH, 2021, 46 (01) : 28 - 36
  • [9] The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease
    Li, Fengqin
    Guo, Hui
    Zou, Jianan
    Chen, Weijun
    Lu, Yijun
    Zhang, Xiaoli
    Fu, Chensheng
    Xiao, Jing
    Ye, Zhibin
    KIDNEY & BLOOD PRESSURE RESEARCH, 2018, 43 (04) : 1310 - 1321
  • [10] Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy
    Tobino, Kyoko
    Muso, Eri
    Iwasaki, Yukako
    Yonemoto, Satomi
    Kasuno, Kenji
    Tsukamoto, Tatsuo
    Nakamura, Hajime
    Tomino, Yasuhiko
    NEPHROLOGY, 2015, 20 (05) : 368 - 374